Loading...

Economou James

Title(s)Vice Chancellor for Research, UCLA
Phone310-825-7575
vCardDownload vCard
    Other Positions
    Title(s)Professor, Surgery

    Title(s)Professor, Microbiology Immunology & Molecular Genetics

    Title(s)Director, Melanoma Program

    Title(s)Chief, Surgical Oncology


    Collapse Research 
    Collapse Research Activities and Funding
    PET IMAGING OF MART TCR-ENGINEERED CD8 T CELL IMMUNOTHERAPY IN MAN
    NIH/NCI R01CA129816Aug 13, 2007 - Jul 31, 2013
    Role: Principal Investigator
    Dendritic Cell-Based Genetic Immunotherapy for Melanoma
    NIH/NCI R01CA079976Jan 1, 1999 - Jan 31, 2008
    Role: Principal Investigator
    Genetic Immunotherapy for Hepatocellular Cancer
    NIH/NCI R01CA077623Apr 1, 1998 - Mar 31, 2006
    Role: Principal Investigator
    UCLA Clinical Scientist Training in Cancer Gene Medicine
    NIH/NCI K12CA076905Sep 30, 1997 - Jun 30, 2008
    Role: Principal Investigator
    UCLA CANCER GENE MEDICINE TRAINING PROGRAM
    NIH/NCI T32CA075956Sep 30, 1997 - Jun 30, 2007
    Role: Principal Investigator
    GENE THERAPY FOR CANCER
    NIH/NCI P01CA059326Sep 30, 1992 - Dec 31, 1998
    Role: Principal Investigator
    THERAPEUTIC REGULATION OF TNF IN IL-2 IMMUNOTHERAPY
    NIH/NCI R29CA050780Jul 1, 1989 - Jun 30, 1994
    Role: Principal Investigator
    REGULATION OF MACROPHAGE FUNCTION BY INTERLEUKIN-2
    NIH/NCI K08CA001360Jul 1, 1988 - Jun 30, 1991
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, Butterfield LH, Maurer DM, Ribas A, Graeber TG, Economou JS. Interleukin 32 expression in human melanoma. J Transl Med. 2019 04 05; 17(1):113. PMID: 30953519.
      View in: PubMed
    2. Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, Cochran AJ, Economou JS, Tumeh PC, Puig-Saus C, Ribas A. Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. Cancer Discov. 2018 08; 8(8):935-943. PMID: 29899062.
      View in: PubMed
    3. Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B. Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. J Immunother. 2018 Jun; 41(5):248-259. PMID: 29470191.
      View in: PubMed
    4. Economou JS, Slamon DJ, Ribas A, Phelps ME. Cancer Research in the 21st Century. Ann Surg. 2016 10; 264(4):555-65. PMID: 27537535.
      View in: PubMed
    5. Economou JS. Engines of Discovery and Innovation. Ann Surg. 2016 09; 264(3):405-12. PMID: 27464615.
      View in: PubMed
    6. Economou JS. Gender bias in biomedical research. Surgery. 2014 Nov; 156(5):1061-5. PMID: 25262221.
      View in: PubMed
    7. Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med. 2014 Apr 05; 12:86. PMID: 24708667.
      View in: PubMed
    8. Jazirehi AR, Kurdistani SK, Economou JS. Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway. J Immunol. 2014 Apr 15; 192(8):3981-9. PMID: 24639349.
      View in: PubMed
    9. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. PMID: 24634374.
      View in: PubMed
    10. Jazirehi AR, Nazarian R, Torres-Collado AX, Economou JS. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. Am J Clin Exp Immunol. 2014; 3(1):43-56. PMID: 24660121.
      View in: PubMed
    11. Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29. PMID: 23519018.
      View in: PubMed
    12. Giannoni F, Hardee CL, Wherley J, Gschweng E, Senadheera S, Kaufman ML, Chan R, Bahner I, Gersuk V, Wang X, Gjertson D, Baltimore D, Witte ON, Economou JS, Ribas A, Kohn DB. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther. 2013 May; 21(5):1044-54. PMID: 23380815.
      View in: PubMed
    13. Economou JS. A society in transition: presidential remarks at the 65th Annual SSO Cancer Symposium. Ann Surg Oncol. 2012 Oct; 19(11):3293-7. PMID: 22805856.
      View in: PubMed
    14. Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS. T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFß) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J Transl Med. 2012 Jun 19; 10:127. PMID: 22713761.
      View in: PubMed
    15. Jazirehi AR, Economou JS. Proteasome inhibition blocks NF-?B and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. Mol Cancer Ther. 2012 Jun; 11(6):1332-41. PMID: 22532603.
      View in: PubMed
    16. Quatromoni JG, Morris LF, Donahue TR, Wang Y, McBride W, Chatila T, Economou JS. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3. J Hematol Oncol. 2011 Nov 23; 4:48. PMID: 22112546.
      View in: PubMed
    17. Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, Haskell J, Vanchinathan V, Chang PL, Tsui S, Konishi T, Comin-Anduix B, Dauphine C, Vargas HI, Economou JS, Ribas A, Bruhn KW, Craft N. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol. 2012 Jan; 132(1):163-9. PMID: 21850019.
      View in: PubMed
    18. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9. PMID: 21558401.
      View in: PubMed
    19. Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res. 2011 Feb 15; 71(4):1406-17. PMID: 21159666.
      View in: PubMed
    20. Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, McBride WH, Schaue D. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1128-35. PMID: 21093169.
      View in: PubMed
    21. Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47. PMID: 20547105.
      View in: PubMed
    22. Baltimore D, Witte ON, Yang L, Economou J, Ribas A. Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma. Pigment Cell Melanoma Res. 2010 Apr; 23(2):288-9. PMID: 20067554.
      View in: PubMed
    23. Ray S, Chhabra A, Mehrotra S, Chakraborty NG, Ribas A, Economou J, Mukherji B. Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol. 2009 Nov-Dec; 27(6):603-13. PMID: 19880048.
      View in: PubMed
    24. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S, Garban HJ, Craft N, Economou JS, Marincola FM, Wang E, Ribas A. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009 Nov 15; 69(22):8693-9. PMID: 19861533.
      View in: PubMed
    25. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 01; 15(19):6267-76. PMID: 19789309.
      View in: PubMed
    26. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009 Jan 01; 15(1):390-9. PMID: 19118070.
      View in: PubMed
    27. Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008 Jul 15; 181(2):1063-70. PMID: 18606658.
      View in: PubMed
    28. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22. PMID: 18452610.
      View in: PubMed
    29. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008 Apr; 31(3):294-309. PMID: 18317358.
      View in: PubMed
    30. Butterfield LH, Ribas A, Potter DM, Economou JS. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother. 2007 Dec; 56(12):1931-43. PMID: 17522860.
      View in: PubMed
    31. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007 Jun; 143(6):958-969. PMID: 17434437.
      View in: PubMed
    32. Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol. 2006 Dec 15; 177(12):8448-55. PMID: 17142742.
      View in: PubMed
    33. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006 May 01; 12(9):2817-25. PMID: 16675576.
      View in: PubMed
    34. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol. 2006 Apr 15; 176(8):4757-65. PMID: 16585569.
      View in: PubMed
    35. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006 Jan 01; 12(1):107-16. PMID: 16397031.
      View in: PubMed
    36. Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother. 2006 Jun; 55(6):663-71. PMID: 16133107.
      View in: PubMed
    37. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27. PMID: 15775996.
      View in: PubMed
    38. Mehrotra S, Chhabra A, Chakraborty A, Chattopadhyay S, Slowik M, Stevens R, Zengou R, Mathias C, Butterfield LH, Dorsky DI, Economou JS, Mukherji B, Chakraborty NG. Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology. 2004 Dec; 113(4):472-81. PMID: 15554925.
      View in: PubMed
    39. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67. PMID: 15314544.
      View in: PubMed
    40. Liao YP, Wang CC, Butterfield LH, Economou JS, Ribas A, Meng WS, Iwamoto KS, McBride WH. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol. 2004 Aug 15; 173(4):2462-9. PMID: 15294960.
      View in: PubMed
    41. Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, Straatsma BR. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials. 2004 Aug; 25(4):400-7. PMID: 15296814.
      View in: PubMed
    42. Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfield LH. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother. 2004 May-Jun; 27(3):191-200. PMID: 15076136.
      View in: PubMed
    43. Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9. PMID: 15067052.
      View in: PubMed
    44. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5902-8. PMID: 14676113.
      View in: PubMed
    45. Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R, Sayre J. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol. 2003 Oct; 14(10):1267-74. PMID: 14551273.
      View in: PubMed
    46. Mehrotra S, Stevens R, Zengou R, Chakraborty NG, Butterfield LH, Economou JS, Dorsky DI, Mukherji B. Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. Cancer Res. 2003 Sep 01; 63(17):5607-14. PMID: 14500402.
      View in: PubMed
    47. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003 Jun 15; 21(12):2415-32. PMID: 12805342.
      View in: PubMed
    48. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003 Mar; 9(3):998-1008. PMID: 12631598.
      View in: PubMed
    49. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003 Feb; 24(2):58-61. PMID: 12547500.
      View in: PubMed
    50. Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene Ther. 2002 Nov; 9(11):875-83. PMID: 12386826.
      View in: PubMed
    51. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002 Feb; 2(1):57-78. PMID: 12108974.
      View in: PubMed
    52. Wargo JA, Economou JS. The status of gene therapy for surgical disease. Adv Surg. 2002; 36:223-57. PMID: 12465553.
      View in: PubMed